In a new study, a fecal microbiota sample taken when eight mice were young and transplanted later to the same mice was associated with fewer cancers, less DNA damage, and longer telomere lengths. The ...

Restoring the gut microbiome to its youthful state may hold the key to slowing aging and preventing liver cancer, one of the ...

Restoring the gut microbiome to its youthful state may hold the key to slowing aging and preventing liver cancer, one of the fastest-growing cancers ...

Restoring the gut microbiome to its youthful state may hold the key to slowing aging and preventing liver cancer, one of the fastest-growing cancers worldwide, according to a study to be presented at ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

- Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. The small ...

The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...

Roivant Discovery Inc. has disclosed PROTACs (proteolysis targeting chimeras) comprising an E3 ubiquitin ligase binding moiety covalently linked to an E3 ubiquitin-protein ligase Mdm2 (Hdm2)-targeting ...

Boehringer Ingelheim’s 2023 was largely marked by the highly anticipated launch of its Cyltezo, the first interchangeable biosimilar to AbbVie’s Humira. But with sales disappointing, the company is ...